U.S. markets open in 7 hours 22 minutes
  • S&P Futures

    3,832.00
    +6.50 (+0.17%)
     
  • Dow Futures

    30,969.00
    +36.00 (+0.12%)
     
  • Nasdaq Futures

    11,711.00
    +36.75 (+0.31%)
     
  • Russell 2000 Futures

    1,741.00
    +2.70 (+0.16%)
     
  • Crude Oil

    111.35
    -0.41 (-0.37%)
     
  • Gold

    1,822.60
    +1.40 (+0.08%)
     
  • Silver

    20.81
    -0.00 (-0.00%)
     
  • EUR/USD

    1.0504
    -0.0021 (-0.20%)
     
  • 10-Yr Bond

    3.2060
    0.0000 (0.00%)
     
  • Vix

    28.36
    +1.41 (+5.23%)
     
  • GBP/USD

    1.2196
    +0.0011 (+0.09%)
     
  • USD/JPY

    135.8400
    -0.2880 (-0.21%)
     
  • BTC-USD

    20,164.77
    -603.82 (-2.91%)
     
  • CMC Crypto 200

    435.58
    -14.49 (-3.22%)
     
  • FTSE 100

    7,323.41
    +65.09 (+0.90%)
     
  • Nikkei 225

    26,813.90
    -235.57 (-0.87%)
     

Legend Biotech Shares Move Higher After Bullish BMO Pitch

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • BMO Capital Markets initiated coverage on Legend Biotech Corporation (NASDAQ: LEGN) with a price target of $77, and an Outperform rating.

  • The analyst says the company's recently approved Carvykti for multiple myeloma is best-in-class late-line CAR T therapy.

  • Related: EMA's CHMP Clears Janssen, Legend's Multiple Myeloma CAR-T Therapy

  • Though the analyst expects a gradual increase in sales due to manufacturing limitations, in the long term, he sees a blockbuster opportunity for Carvykti as the leader in multiple myeloma CAR T therapies with peak sales of around $5.5 billion.

  • Legend and its collaborator Janssen, a unit of Johnson & Johnson (NYSE: JNJ), are working on expanding Carvykti's addressable population through approvals in earlier lines and Japan & China that will bolster additional growth.

  • The analyst also notes upcoming data readouts from earlier-line therapies that can drive short-term upside.

  • Price Action: LEGN shares are up 6.84% at $45.90 during the market session on the last check Friday.

Latest Ratings for LEGN

Date

Firm

Action

From

To

Mar 2022

Morgan Stanley

Maintains

Overweight

Jan 2022

Morgan Stanley

Upgrades

Equal-Weight

Overweight

Jan 2022

Morgan Stanley

Downgrades

Overweight

Equal-Weight

View More Analyst Ratings for LEGN

View the Latest Analyst Ratings

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.